XINGTAI XINGJIU NEW MATERIAL TECHNOLOGY CO., LTD

Deferasirox is an iron chelator product. It is the first oral iron displacing agent approved by the US FDA for routine use. It is approved for use in patients ≥2 years of age and chronic iron overload caused by blood transfusion. It is used in Europe. It is recommended as a first-line drug for thalassemia iron overload patients over 6 years old. Chemicalbook is currently undergoing clinical research in China; Phase II and III clinical trials and pharmacokinetic studies have shown that it has good safety and tolerability, and It can significantly reduce the iron load of the heart and liver, and is easy to be accepted by patients. At the same time, it also has pharmacological properties such as antifungal (such as Mucor growing in an iron-rich environment), anti-cell proliferation, anti-malarial, anti-oxidative stress injury, anti-cytotoxic-induced apoptosis, etc.; it can be used for secondary Treatment of diseases such as hemochromatosis and delayed cutaneous porphyria.
Functions: